<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414944</url>
  </required_header>
  <id_info>
    <org_study_id>CRTOG1602</org_study_id>
    <nct_id>NCT03414944</nct_id>
  </id_info>
  <brief_title>Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases</brief_title>
  <acronym>SMART-Brain</acronym>
  <official_title>Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases,A Phase I,One-arm Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain metastases are the most common intracranial tumors in adults. Whole-brain radiation
      therapy (WBI) increases the median survival of patients with brain metastases up to 3-6
      months, but WBI can lead to the decline of cognition and quality of life, with short local
      control time. The use of SIB(simultaneous integrated boost) technology can increase the local
      control rate. Hippocampus avoidance can effectively reduce the cognitive impairment caused by
      WBI.This study was designed to evaluate the safety and efficacy of selective brain
      radiotherapy (EBI)(based on SIB and hippocampus, inner ear avoidance )in NSCLCs with limited
      brain metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective phase 1 study evaluating the safety and efficacy of selective brain
      radiotherapy in NSCLCs with limited brain metastases, patients will received selective brain
      radiotherapy based on SIB and hippocampus, inner ear avoidance.

      Prescription dose: Gross tumor (PGTV) 40-50 Gy/10 fractions/2 weeks + EBI (PCTV) 30 Gy/10
      fractions/2 weeks.

      OARs dose limits: Hippocampus D100%≤10Gy, Dmax≤17Gy,Inner ear: Dmean ≤15Gy. All patients were
      observed and recorded daily for acute radiation impairment during radiotherapy. Follow-up
      every 2 months will be performed after radiotherapy.

      The primary endpoint:Acute and chronic radiation response, QOL in patients, vestibular
      function,neurocognitive function based on mini-mental state examination(MMSE) questionnaires,
      hearing.

      The secondary endpoint included:objective response rate (ORR);intracranial progression-free
      survival (iPFS); OS (defined as the time from study beginning to death from any cause).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>iPFS</measure>
    <time_frame>From date of treatment begining until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
    <description>Intracranial progression free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>SMART-Brain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>selective brain radiotherapy based on SIB and hippocampus, inner ear avoidance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SMART-Brain</intervention_name>
    <description>Prescription dose: Gross tumor (PGTV) 40-50 Gy/10 fractions/2 weeks + EBI (PCTV) 30 Gy/10 fractions/2 weeks.
OARs dose limits: Hippocampus D100%≤10Gy, Dmax≤17Gy,Inner ear: Dmean ≤15Gy.</description>
    <arm_group_label>SMART-Brain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        histologically or cytologically confirmed NSCLC with MRI confirmed new brain metastases a
        life expectancy of at least 3 months; adequate organ function according to the National
        Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0.

        Exclusion Criteria:

        radiologically or pathologically confirmed metastases in the spinal cord or meninges
        obvious hernia formation risk previously received brain surgery or radiotherapy a history
        or presence of poorly controlled systemic diseases pregnant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuan Shuanghu, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Shandong cancer hospital and constitute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang Aijiang, doctor</last_name>
    <phone>+860531-67626932</phone>
    <email>xzjaj@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuan Shuanghu, doctor</last_name>
    <phone>+86 0531-67626931</phone>
    <email>yuanshuanghu@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jin'an</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Aijun, Doctor</last_name>
      <phone>+86 0531-67626932</phone>
      <email>xzjaj@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuan Shuanghu, Doctor</last_name>
      <phone>+86 0531-67626931</phone>
      <email>yuanshuanghu@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006 Jun 7;295(21):2483-91.</citation>
    <PMID>16757720</PMID>
  </results_reference>
  <results_reference>
    <citation>Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998 Nov 4;280(17):1485-9.</citation>
    <PMID>9809728</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009 Nov;10(11):1037-44. doi: 10.1016/S1470-2045(09)70263-3. Epub 2009 Oct 2.</citation>
    <PMID>19801201</PMID>
  </results_reference>
  <results_reference>
    <citation>Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol. 2006 Mar 10;24(8):1305-9. Review.</citation>
    <PMID>16525186</PMID>
  </results_reference>
  <results_reference>
    <citation>Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004 Jan 1;22(1):157-65.</citation>
    <PMID>14701778</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller JA, Kotecha R, Suh JH. Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. Cancer. 2016 Oct 15;122(20):3243-3244. doi: 10.1002/cncr.30188. Epub 2016 Jul 8.</citation>
    <PMID>27392066</PMID>
  </results_reference>
  <results_reference>
    <citation>Ozdemir Y, Yildirim BA, Topkan E. Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors. J Neurooncol. 2016 Sep;129(2):329-35. doi: 10.1007/s11060-016-2179-9. Epub 2016 Jun 15.</citation>
    <PMID>27306442</PMID>
  </results_reference>
  <results_reference>
    <citation>Mekhail T, Sombeck M, Sollaccio R. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. Curr Oncol Rep. 2011 Aug;13(4):255-8. doi: 10.1007/s11912-011-0180-1.</citation>
    <PMID>21584645</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>ShuanghuYuan</investigator_full_name>
    <investigator_title>Director, Head of of Radiation Oncology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Brain metastases</keyword>
  <keyword>SIB</keyword>
  <keyword>hippocampus avoidance</keyword>
  <keyword>inner ear avoidance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

